Nature Reviews Disease Primers 3, 16096 (2017)
In the version of the article originally published, a typographical error has now been corrected. The statement now reads: Approval of ibrutinib as initial therapy was based on the results of a randomized trial that showed a significant improvement in median PFS and overall survival in patients. ≥65 years of age without del(17p) who were treated indefinitely with ibrutinib than in patients treated for up to 48 weeks with chlorambucil146.
Additional information
The online version of the original article can be found at 10.1038/nrdp.2016.96
Rights and permissions
About this article
Cite this article
Kipps, T., Stevenson, F., Wu, C. et al. Correction: Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3, 17008 (2017). https://doi.org/10.1038/nrdp.2017.8
Published:
DOI: https://doi.org/10.1038/nrdp.2017.8
- Springer Nature Limited
This article is cited by
-
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
Leukemia (2024)
-
Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression
Cancer Gene Therapy (2023)
-
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
Nature Communications (2023)
-
Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target
Leukemia (2021)
-
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)
Leukemia (2021)